Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY – Get Free Report) was the recipient of a significant increase in short interest in May. As of May 29th, there was short interest totaling 74,992 shares, an increase of 173.1% from the May 14th total of 27,456 shares. Based on an average trading volume of 283,609 shares, the days-to-cover ratio is presently 0.3 days. Approximately 0.0% of the shares of the stock are short sold.
Wall Street Analyst Weigh In
SGIOY has been the subject of several research reports. Zacks Research upgraded shares of Shionogi & Co., Ltd. Unsponsored ADR from a “strong sell” rating to a “hold” rating in a research report on Monday, May 25th. The Goldman Sachs Group raised shares of Shionogi & Co., Ltd. Unsponsored ADR to a “hold” rating in a research note on Wednesday, April 8th. Two equities research analysts have rated the stock with a Hold rating, According to data from MarketBeat.com, the company has an average rating of “Hold”.
Check Out Our Latest Research Report on SGIOY
Shionogi & Co., Ltd. Unsponsored ADR Trading Down 0.3%
Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY – Get Free Report) last posted its quarterly earnings data on Tuesday, May 12th. The company reported $0.18 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.15 by $0.03. Shionogi & Co., Ltd. Unsponsored ADR had a return on equity of 14.09% and a net margin of 41.08%.The firm had revenue of $881.71 million for the quarter, compared to the consensus estimate of $895.52 million. Research analysts predict that Shionogi & Co., Ltd. Unsponsored ADR will post 0.81 earnings per share for the current year.
About Shionogi & Co., Ltd. Unsponsored ADR
Shionogi & Co, Ltd. is a Japan-based pharmaceutical company that conducts research, development, manufacturing and marketing of prescription drugs and vaccines. Established in the late 19th century, the company has expanded its focus beyond domestic markets to become a global player in pharmaceuticals, with particular expertise in anti-infectives, pain management, cardiovascular and central nervous system disorders.
The company’s product portfolio spans both established and innovative therapies.
Further Reading
- Five stocks we like better than Shionogi & Co., Ltd. Unsponsored ADR
- SMX: Can Molecular Tracking Technology Become the Next Moonshot?
- Boeing’s Unseen Rebound: Why the Headlines Are Wrong
- Applied Digital Is Building a $36 Billion AI Real Estate Empire
- Why Oracle’s 10% Drop May Be Telling the Wrong Story
Receive News & Ratings for Shionogi & Co. Ltd. Unsponsored ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shionogi & Co. Ltd. Unsponsored ADR and related companies with MarketBeat.com's FREE daily email newsletter.
